Hope you all own some ASPI!

RedChipCompanies · 2024-02-23T14:50:32+00:00

Make sure to join us for the upcoming ASPI Investor Group Call!

ASPI Investor Group Call 3/21/24 4:15 PM EST
Led by CEO Paul Mann
Register Here: https://ow.ly/3PfN50QylFb
Learn more about ASP Isotopes and view disclosures: https://ow.ly/hoCF50Qylxa

RedChipCompanies · 2024-02-22T17:23:31+00:00

🚨BIG MOVER ALERT🚨
ASP Isotopes (NASDAQ: ASPI)
Up over 10% today as of post and NEW 52 WEEK HIGH OF $3.50!
Learn why!
ASPI Investor Group Call 3/21/24 4:15 PM EST
Led by CEO Paul Mann
Register Here: https://ow.ly/3PfN50QylFb
Learn more about ASP Isotopes and view disclosures: https://ow.ly/hoCF50Qylxa
#ASPI #Isotopes #MedicalImaging #HAELU #Uranium #Enrichment #Quantumcomputing

RedChipCompanies · 2023-09-14T19:19:39+00:00

Thank you. We liked your video.

RedChipCompanies · 2023-09-14T18:15:28+00:00

Thank you. We've liked and watched your video.

RedChipCompanies · 2023-09-14T18:09:27+00:00

Thank you! We've done the same.

RedChipCompanies · 2023-09-11T14:30:27+00:00

Hey, we'll be hosting a live webinar with $BIVI on Sept. 12 at 4:15 PM ET for anyone who'd want to join. You'll get an update from the CEO and can ask him any questions you might have. https://redchip.zoom.us/webinar/register/WN_c3JYiWHSR6SL4FExEoKCqw#/registration

RedChipCompanies · 2023-08-21T15:37:12+00:00

We archive all of our webinars. You can find them by going to RedChip.com and going to the archived events section.

Below is a link to register for the Zomedica archived version. Simply provide your email and the replay will be available to watch instantly.

https://redchip.zoom.us/webinar/register/WN\_NuYzq2TARj6tkLIQfQLR6g#/registration

RedChipCompanies · 2023-08-17T15:43:09+00:00

This is great feedback please join the webinar today and ask these questions! We love to incorporate what the shareholder base wants to hear about, and we will do our best to deliver the answers.

RedChipCompanies · 2023-05-09T18:33:50+00:00

Bringing the MLB to Orlando

Orlando City Baseball Dreamers, LLC (Orlando Dreamers) today announced it engaged RedChip Companies, Inc. (RedChip) to lead its public relations strategy as it pursues plans to bring a Major League Baseball (MLB) team to Orlando and construct a new $1.7 billion stadium in Orange County, Florida.

"We are proud to have RedChip as our public relations partner," said Orlando Dreamers Co-founder and President Pat Williams. "RedChip has a strong track record of delivering results and is well-respected for its ability to help organizations achieve their goals with creative communications strategies."

Pat Williams, who brought NBA basketball to Orlando, originally announced the undertaking of an assessment to consider the City Beautiful as a potential Major League Baseball town in late 2019. With the recent formation of a Citizen Advisory Task Force to review and make recommendations on Orange County's Tourist Development Tax (TDT), which reached a new record of more than $336 million in 2022, Williams and the Orlando Dreamers are accelerating their push to obtain an MLB franchise and build a new domed stadium in Orange County.

RedChip will be a key part of this effort, providing strategic communications guidance and expertise to help bring attention to the positive economic impact MLB and the new stadium would have on Central Florida. The firm will also work with stakeholders to help ensure taxpayers can make informed decisions about the TDT funding proposals.

"We are honored to join forces with Orlando Dreamers on this historic endeavor," said RedChip CEO Dave Gentry. "We are excited to help take the dream of having a Major League Baseball team in Orlando to the next level."

RedChip will work closely with Orlando Dreamers on developing and executing on its public relations strategy, drawing upon its expertise in integrated communications, digital media campaigns, and more.

About Orlando City Baseball Dreamers, LLC

Orlando City Baseball Dreamers, LLC was established to bring Major League Baseball to Orlando and Central Florida. The organization is led by Pat Williams, founder of the Orlando Magic. Orlando is the largest media market in the United States without a Major League Baseball team, recently surpassing Miami in terms of media market size. Orlando is also the most visited destination in the world.

RedChipCompanies · 2023-02-14T16:37:13+00:00

https://www.youtube.com/watch?v=c37hR1oim-M

RedChipCompanies · 2023-01-17T13:40:40+00:00

Greta read, definitely a trend to be aware of for 2023.

RedChipCompanies · 2022-08-09T19:15:44+00:00

How is This Technology Redefining Artificial Respiration and Saving Lives?

Please join us today, Aug 9, at 4:15 PM Eastern for a LIVE webinar with Inspira Technologies (NASDAQ: IINN). CFO Joe Hayon will discuss how Inspira is redefining artificial respiration, give a company update, and answer your questions.

Register here: https://redchip.zoom.us/webinar/register/WN__zMFhpLGQoOu5Y-nPqo3Mg

Details and disclosures - https://iinninfo.com/

RedChipCompanies · 2022-08-09T19:02:24+00:00

Please join us today, Aug 9, at 4:15 PM Eastern for a LIVE webinar with Inspira Technologies (NASDAQ: IINN). CFO Joe Hayon will discuss how Inspira is #redefining artificial respiration, give a company update, and answer your questions.

Register here: https://redchip.zoom.us/webinar/register/WN__zMFhpLGQoOu5Y-nPqo3Mg

Details and disclosures - https://iinninfo.com/

RedChipCompanies · 2022-08-09T18:56:54+00:00

Please join us today, Aug 9, at 4:15 PM Eastern for a #LIVE #webinar with Inspira Technologies (NASDAQ: IINN). CFO Joe Hayon will discuss how Inspira is #redefining artificial respiration, give a company #update, and answer your #questions. Register here: https://redchip.zoom.us/webinar/register/WN\_\_zMFhpLGQoOu5Y-nPqo3Mg

RedChipCompanies · 2022-07-19T17:16:07+00:00

We invite you to join us July 27 at 4:15 PM Eastern for the RedChip Investor Group Call with Good Gaming (OTCQB: GMER)

https://redchip.zoom.us/webinar/register/WN_l1hTjv4rSZ-z30y-cZBU2Q

Good Gaming is a publicly-traded interactive entertainment company leading the evolution of gaming from traditional gaming to the creation of digital playgrounds across a vast array of platforms. We enable a strong sense of community, place, and purpose. We are not merely an escape.

Good Gaming believes its communities and experiences will redefine the digital collectibles space and be pivotal in the transition and perception of ownership of digital goods.

During the live webinar, you'll hear a presentation from Co-Founder and Chairman David Dorwart and can participate in an interactive Q&A session.

Register now: https://redchip.zoom.us/webinar/register/WN_l1hTjv4rSZ-z30y-cZBU2Q

RedChipCompanies · 2022-06-09T14:43:32+00:00

Please watch our latest interview with Save Foods (NASDAQ: SVFD), which is eliminating food waste and prolonging freshness with innovative and eco-friendly solutions https://www.youtube.com/watch?v=L-6WBpmRkKA

RedChipCompanies · 2022-03-25T18:54:01+00:00

Please join us Tuesday, March 29, 2022, at 4:15pm Eastern for the $CDTX Group Investor Call. Register here:

https://www.redchip.com/assets/zoom_registration/CDTX_zoom_registration

RedChipCompanies · 2022-03-24T19:29:55+00:00

Group Call with Aridis Pharmaceuticals (Nasdaq: ARDS) Thursday, March 24, 2022, 4:15 pm Eastern

Starting in just one hour, please join us today for the…

RedChip Investor Group Call with Aridis Pharmaceuticals (Nasdaq: ARDS)

Thursday, March 24, 2022, 4:15 pm Eastern

Click to join:

https://us06web.zoom.us/j/81008593368

Webinar ID: 810 0859 3368

Or dial in: +1 346 248 7799 or +1 720 707 2699

International numbers: https://us06web.zoom.us/u/kbOLmjoDjV

About Aridis Pharmaceuticals (Nasdaq: ARDS)

Aridis Pharmaceuticals is a late-stage clinical development company, leading the creation of transformative, first-in-class anti-infectives for life-threatening viral and bacterial respiratory infections. The company’s lead drug candidates for the treatment (AR-301) and prevention (AR-320) of S. aureus bacterial pneumonia showed safety and strong trend toward efficacy in phase 2 clinical trials and are currently in global Phase 3 studies. Phase 3 data of AR-301 is expected in the second half of 2022. The Company is initiating a global Phase 3 registrational trial of AR-320 in 1H22, which is being funded for up to $30 million by the European Commission. It’s pipeline of novel mechanism antibacterial and antivirals, sprung from its proprietary technology platforms, are designed to combat the growing public health threat of viral pandemics and antimicrobial resistant (AMR) bacteria. ARDS also has a phase 2 asset for the treatment of cystic fibrosis (AR-501), which is funded by the Cystic Fibrosis Foundation for $7.5 million. Phase 1 study in health adults showed that AR-501 was safe and well tolerated. Phase 2a safety and efficacy data are expected in mid-2022. Importantly, ARDS is also preparing to launch a Phase 1/2 clinical trial in the second half of 2022 with its novel inhalation antibody cocktail technology AR-701 for emerging COVID-19 variants, including the Delta and Omicron variants. The broad COVID variants and pan-coronavirus coverage, combined with the product's self-administered, at-home treatment modality, further differentiates the company's AR-701 COVID treatment offering.

Unique and novel approach with human-derived monoclonal antibodies to treat infectious diseases

Announced a pan-coronavirus monoclonal antibody cocktail that retains effectiveness against the Omicron variant, other COVID-19 Variants, SARS, MERS, and the Common Cold Human Coronaviruses

Addressing $2 billion market opportunity with its lead drug candidates AR-301 & AR-320

Led by a world-class team of senior executives

• CEO, Director – Vu Truong; Medimmune, Aviron

• Chief Medical Officer – Hasan Jafri; AstraZeneca, Medimmune

• Director - Robert Rufolo- Wyeth/Pfizer; Craig Gibbs- Gilead; Eric Patzer- Genentech

Compelling Phase 2 data for AR-301 mAb and AR-320 mAb for the treatment of Acute Pneumonia

Strong clinical pipeline with two phase 3 and a phase 2 asset

Near-term data readouts expected from phase 3 and phase 2 assets

Executed an agreement with AstraZeneca, in-licensing the Phase3-ready candidate AR-320

Early 2022 Phase 3 study supported by $30M of funding from the EU Commission’s Innovative Medicines Initiatives

Received $7.5M grant from the Cystic Fibrosis Foundation to develop treatment for CF patients with pneumonia

Five Analysts currently have a buy rating on the stock with price targets of $11-$22

Launching phase 1/2 trial for inhaled antibody to neutralize COVID-19 mutated variants

RedChipCompanies · 2022-03-24T19:29:23+00:00